LJPC-401
Sponsors
La Jolla Pharmaceutical Company
Conditions
Beta-ThalassemiaHereditary Hemochromatosis
Phase 2
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
TerminatedNCT03381833
Start: 2017-11-30End: 2020-01-14Updated: 2021-07-29
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
CompletedNCT03395704
Start: 2017-11-29End: 2019-10-28Updated: 2022-06-09